



# BerGenBio ASA: Share capital increase

**Bergen, Norway, 3 February 2022** - Reference is made to the stock exchange notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 27 January 2022 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise of options pursuant to the Company's share option program. A total of 100,000 options were exercised and 100,000 new shares were issued at an average subscription price of NOK 15.33 per share.

The share capital increase has been duly registered in the Norwegian Register of Business Enterprises. Following such registration, the Company's share capital is NOK 8,855,525.50 divided into 88,555,255 shares, each with a nominal value of NOK 0.10.

-End-

## Contacts

Martin Olin  
CEO, BerGenBio ASA  
[ir@bergenbio.com](mailto:ir@bergenbio.com)

Rune Skeie  
CFO, BerGenBio ASA  
[Rune.skeie@bergenbio.com](mailto:Rune.skeie@bergenbio.com)

## Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

**This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.**